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Abstract
Estrogen and estrogen metabolite-induced reactive oxygen species generation can promote oxidative DNA base
damage. If unrepaired, base damaging lesions could accelerate mutagenesis, leading to a ‘‘mutator phenotype’’
characterized by aggressive behavior in estrogen-estrogen receptor (ER)-driven breast cancer. To test this
hypothesis, we investigated 1406 ER+ early-stage breast cancers with 20 years’ long-term clinical follow-up
data for DNA polymerase b (pol b), flap endonuclease 1 (FEN1), AP endonuclease 1 (APE1), X-ray cross-
complementation group 1 protein (XRCC1), single-strand monofunctional uracil glycosylase-1 (SMUG1), poly
(ADP-ribose) polymerase 1 (PARP1), ataxia telangiectasia mutated and Rad3 related (ATR), ataxia telangi-
ectasia mutated (ATM), DNA-dependent protein kinase catalytic subunit (DNA-PKcs), Chk1, Chk2, p53, breast
cancer susceptibility gene 1 (BRCA1), and topoisomerase 2 (TOPO2) expression. Multivariate Cox propor-
tional hazards model was used to calculate a DNA repair prognostic index and correlated to clinicopathological
variables and survival outcomes. Key base excision repair (BER) proteins, including XRCC1, APE1, SMUG1,
and FEN1, were independently associated with poor breast cancer-specific survival (BCSS) ( ps £ 0.01). Mul-
tivariate Cox model stratified patients into four distinct prognostic sub-groups with worsening BCSS
( ps< 0.01). In addition, compared with prognostic sub-group 1, sub-groups 2, 3, and 4 manifest increasing
tumor size, grade, mitosis, pleomorphism, differentiation, lymphovascular invasion, high Ki67, loss of Bcl-2,
luminal B phenotype ( ps£ 0.01), and poor survival, including in patients who received tamoxifen adjuvant
therapy ( p< 0.00001). Our observation supports the hypothesis that BER-directed stratification could inform
appropriate therapies in estrogen-ER-driven breast cancers. Antioxid. Redox Signal. 21, 2262–2268.
Introduction
Chronic estrogen exposure increases the risk of breastcancer (9). Although estrogen/estrogen receptor a
(ERa)-dependent cellular proliferation signaling is widely
known to promote breast cancer development, there is
growing evidence for an ERa-independent mechanism pro-
moting estrogen-induced breast cancer development (9). The
estrogen metabolites such as 2,3-quinone catechols and 3,4-
quinone catechols can induce the generation of reactive ox-
ygen species (ROS), which, in turn, promote oxidative DNA
base damage (3, 5). Estrogen metabolites can also directly
induce genomic DNA damage (3, 5). The 3,4-quinones cat-
echols can interact with adenine and guanine bases to form
unstable depurinating 4-OH-E2/E1-1-N3 adenine and 4-
OHE2/E1-1-N7 adducts. Spontaneous depurination of ad-
ducts can generate potentially mutagenic apurinic sites (also
known as AP sites). Breast cancer patients or those at risk of
developing breast cancer have been found to have higher
levels of depurinating estrogen–DNA adducts in their urine
compared with those not at increased risk for breast cancer
development.
ROS generation and depurination induced by estrogen
metabolites is an important source of DNA base damage,
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which is a strong stimulus for activation of DNA base excision
repair (BER), a complex pathway that includes key enzymes,
including AP endonuclease 1 (APE1), DNA polymerase b
(pol b), flap endonuclease 1 (FEN1), poly (ADP-ribose)
polymerase 1 (PARP1), X-ray cross-complementation group
1 protein (XRCC1), and DNA ligases (4). If BER is sub-
optimal, DNA repair intermediates may be converted to sin-
gle-strand breaks (SSB) and then to double-strand breaks
(DSBs) during replication. DSBs activate key DNA dam-
age sensing ataxia telangiectasia mutated (ATM), DNA-
dependent protein kinase catalytic subunit (DNA-PKcs), and
ataxia telangiectasia mutated and Rad3 related (ATR) protein
kinases. Activated ATR and ATM phosphorylate Chk1 or
Chk2, respectively; these, in turn, modulate a number of other
proteins involved in DNA repair, cell cycle control, and ap-
optosis (7). Our hypothesis is that sub-optimal DNA repair
may accelerate ROS-induced mutagenesis and lead to a mu-
tator phenotype characterized by aggressive behavior in es-
trogen/ER-driven breast cancer. We investigated 1406 ER+
early-stage breast cancers with 20 years’ long-term clinical
follow-up data for pol b, FEN1, APE1, XRCC1, single-strand
monofunctional uracil glycosylase-1 (SMUG1), PARP1, ATR,
ATM, DNA-PKcs, Chk1, Chk2, p53, breast cancer susceptibility
gene 1 (BRCA1), and topoisomerase 2 (TOPO2) expression.
Deregulated BER is independently associated
with poor survival in ER + breast cancers
The initial multivariate model included Pol b, FEN1,
APE1, XRCC1, SMUG1, PARP1, ATR, ATM, CHK1,
CHK2, p53, BRCA1, DNA-PKcs, TOPO2, lymph node sta-
tus, and histological grade. Nonsignificant markers were then
removed using a backward stepwise exclusion method until
only significant markers remained. As shown in Table 1, low
XRCC1 ( p< 0.01), low APE1 ( p < 0.01), low SMUG1
( p< 0.01), and high FEN1 ( p < 0.01) remain independently
associated with poor breast cancer-specific survival (BCSS).
Lymph node stage ( p < 0.00001) and histological grade
( p< 0.00001) also remain independently associated with
poor BCSS.
BER prognostic index stratifies patients into distinct
prognostic groups in ER + breast cancers
A BER prognostic index score (see Notes section) incor-
porating XRCC1, APE1, SMUG1, and FEN1 was developed
and can be described by the following formula:
BER prognostic index score=XRCC1 (high: - 0.20, low: 1)
+FEN1 (high: 0.20, low: 1)+SMUG1 (high: - 0.21, low: 1)
+APE1 (high: - 0.25, low: 1)
Sub-group 1 was defined as tumors with BER prognostic
index score ranging from - 0.46 to 0.34. Sub-group 2 was
defined as tumors with BER prognostic index score ranging
from 0.74 to 1.59. Sub-group 3 was defined as tumors with
BER prognostic index score ranging from 1.95 to 2.80. Sub-
group 4 was defined as tumors with a BER prognostic index
score of more than 3.2.
Survival analysis was conducted for the individual sub-
groups. As shown in Figure 1, the BER prognostic index
score stratified patients into four distinct sub-groups. Sub-
group 1 had the best survival, whereas sub-group 4 had the
worst survival ( p < 0.000001). The survival of patients in
sub-group 2 ( p < 0.001) and sub-group 3 ( p < 0.000001) re-
mains poor compared with sub-group 1. In patients who are at
high risk (Nottingham index score > 3.4) and did not receive
adjuvant endocrine therapy, the survival of patients in sub-
group 4 remains poor (Fig. 2A). Together, the data provides
evidence that BER expression status may have prognostic
significance in patients. We also evaluated whether BER had
predictive significance in patients with ER + tumours who
received adjuvant tamoxifen therapy. As shown in Figure 2B,
patients in sub-group 4 had the worst survival and patients in
sub-groups 2 and 3 had intermediate prognosis compared
with sub-group 1. These data suggest that BER expression
may predict benefits from endocrine therapy.
Deregulated BER is associated
with aggressive ER + breast cancers
The data presented earlier suggest that BER expression
status may be a promising biomarker. To provide additional
Table 1. Multivariate Cox Proportional Hazards Model in Estrogen Receptor-Positive Breast Cancers
Variables Beta p-Value Risk ratio Risk ratio 95% lower Risk ratio 95% upper
XRCC1 - 0.203954 0.000219 0.815500 0.731907 0.908640
FEN1 0.199727 0.004731 1.221069 1.063067 1.402556
SMUG1 - 0.210251 0.003919 0.810381 0.702510 0.934816
APE1 - 0.245472 0.000754 0.782335 0.678241 0.902406
Lymph node stage (continuous) 0.705445 0.0000001 2.024747 1.662938 2.465276
Histological grade 0.616616 0.0000001 1.852647 1.510526 2.272256
Bold values indicate significant p-values.
APE1, AP endonuclease 1; FEN1, flap endonuclease 1; SMUG1, single-strand monofunctional uracil glycosylase-1; XRCC1, X-ray
cross-complementation group 1 protein.
Innovation
The role of estrogen receptor (ER)-dependent cellular
proliferation signaling is well established in breast cancer
pathogenesis; however, very little is known about the
clinical relevance of ER-independent mechanisms. Es-
trogen and estrogen metabolites induce reactive oxygen
species generation that can promote oxidative DNA base
damage which is repaired by base excision repair (BER).
Impaired BER, therefore, could accelerate mutagenesis
and promote a mutator phenotype in estrogen-driven
breast cancers. The authors provide the first comprehen-
sive clinical evidence that altered BER expression may be
associated with aggressive estrogen-ER-driven breast
cancers. Stratification by BER status may enable person-
alization of therapy in estrogen-driven breast cancers.
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FIG. 1. BER and ER1
breast cancer. Kaplan–Meier
curves showing BCSS strati-
fied based on BER prognostic
index score. BCSS, breast can-
cer specific survival; BER,
base excision repair; ER, es-
trogen receptor. To see this
illustration in color, the reader
is referred to the web ver-
sion of this article at www
.liebertpub.com/ars
FIG. 2. Kaplan–Meier curves showing BCSS stratified based on BER prognostic index score in patients who did not
receive tamoxifen (A) and who received adjuvant tamoxifen (B). To see this illustration in color, the reader is referred to
the web version of this article at www.liebertpub.com/ars
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evidence that BER may impact aggressive biology, we con-
ducted clinicopathological association studies in the various sub-
groups. As shown in Table 2, larger size, higher grade, higher
mitotic index, poor differentiation, high Ki67, Bcl-2 negativity,
HER-2 overexpression, luminal B, and luminal B-Her 2 over-
expression were more likely in sub-group 4, or 3 or 2 tumors
when compared with tumors in sub-group 1 (ps<0.05). Inter-
estingly, tubular, low grade, low mitotic index, and luminal A
tumors were more common in sub-group 1 tumors.
Concluding Remarks and Future Directions
Proficient DNA damage signaling and DNA repair ma-
chinery is critical for processing estrogen/estrogen metabo-
lite-induced oxidative DNA base damage in cells (3, 5). In
breast epithelial cells chronically exposed to estrogens, sub-
optimal DNA repair and the resulting genomic instability
may lead to accumulation of genetic mutations that eventu-
ally drive a cancerous phenotype. This is the first study
that evaluates expression of BER in a large cohort of ERa-
positive breast tumors. Here, we provide the first evidence
that BER is deregulated in a proportion of ER + tumors. We
found impaired BER to be associated with aggressive phe-
notype and poor survival. We found that ER + breast tumors
could be categorized into four discrete subgroups based on
BER protein levels. In addition to prognostic differences,
significant differences in clinical characteristics were ob-
served between subgroups. As expected, subgroups with
poorer prognosis had significantly larger tumor size, higher
grade, and other aggressive features. The clinicopathological
associations shown here provide further evidence that BER
deregulation may be involved in estrogen/ER-driven breast
cancer pathogenesis and promote a mutator phenotype.
However, detailed mechanistic studies in preclinical models
will be required to confirm our hypothesis. A limitation to our
study is retrospective in historical cohorts, albeit with 20
years’ long-term follow-up data. Therefore, it would be es-
sential to investigate the prognostic significance of BER in a
Table 2. Clinicopathological Association in the Various Sub-Groups
Factors Expression
Sub-group 1
n (%)
Sub-group 2
n (%)
Sub-group 3
n (%)
Sub-group 4
n (%) p-Value
Lymph nodes 0.645
0 201 (63) 194 (61) 72 (53) 33 (63)
1–3 98 (30) 104 (32) 51 (37) 15 (29)
> 3 23 (7) 22 (7) 12 (10) 4 (8)
Tumor size 0.018
£ 1 cm 44 (14) 38 (12) 12 (10) 4 (8)
> 1–2 cm 18 (56) 155 (49) 62 (46) 25 (48)
> 2–5 cm 95 (29) 118 (37) 59 (43) 21 (40)
> 5 cm 2 (1) 8 (2) 3 (2) 3 (6)
Grade 0.000002
G1 (low) 87 (27) 58 (18) 23 (17) 9 (17)
G2 (intermediate) 152 (47) 136 (43) 45 (33) 15 (29)
G3 (High) 82 (26) 125 (39) 68 (50) 28 (54)
Mitosis 0.00008
M1 (low, < 10) 178 (56) 129 (39) 46 (34) 19 (36)
M2 (medium, 10–18) 74 (23) 114 (36) 56 (42) 21 (40)
M3 (high, > 18) 74 (23) 114 (36) 56 (42) 21 (40)
Pleomorphism 0.0005
Low 10 (3) 8 (2) 5 (4) 1 (2)
Moderate 185 (58) 161 (51) 49 (36) 20 (38)
High 126 (39) 148 (47) 81 (60) 31 (60)
Differentiation 0.017
Well differentiated 24 (8) 24 (8) 7 (5) 1 (2)
Moderate differentiated 144 (45) 106 (33) 48 (36) 16 (31)
Poor differentiated 153 (48) 188 (59) 80 (59) 35 (67)
LVI Presence 98 (30) 95 (30) 63 (46) 20 (39) 0.003
Tumor type 0.006
Invasive ductal (NST) 130 (44) 149 (52) 72 (57) 26 (57)
Medullary 0 (0) 3 (1) 1 (1) 1 (2)
Tubular 91 (31) 61 (21) 37 (29) 5 (21)
Invasive lobular 44 (15) 39 (14) 11 (9) 6 (13)
Others 29 (10) 35 (12) 6 (5) 8 (17)
Ki67 High expression 147 (53) 164 (60) 75 (65) 418 (59) 0.012
Bcl2 Negative expression 54 (18) 47 (16) 38 (30) 156 (20) 0.0004
HER2 Overexpression 13 (4) 17 (5) 14 (10) 1 (2) 0.033
Molecular sub-types 0.014
Luminal A 153 (51) 132 (45) 53 (41) 14 (32)
Luminal B high Ki67 132 (44) 146 (49) 63 (48) 29 (66)
Luminal B-HER2 over expression 13 (5) 17 (6) 14 (11) 1 (2)
Bold values indicate significant p-values.
NST, non-specific type.
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more modern cohort where patients routinely receive adju-
vant anthracycline-based chemotherapy schedules followed
by aromatase inhibitor therapy in high-risk situations. How-
ever, it is important to note that in the group which received
no adjuvant endocrine therapy, impaired BER remains as-
sociated with poor survival, suggesting that BER is an im-
portant prognostic biomarker. Interestingly, in patients who
received tamoxifen, BER deregulation remains associated
with poor survival, implying that BER may also have pre-
dictive significance in patients and the data suggest that ad-
ditional therapy would be required to improve outcomes in
such patients.
The mechanism for endocrine resistance in BER-impaired
cells is largely unknown. However, recent studies suggest an
interaction between BER and ER. For example, FEN1 has been
shown to regulate ER-induced transcriptional response by en-
hancing the interaction of ER with estrogen response elements-
containing DNA (6). Moreover, the mechanism of regulation of
BER in ER+ tumours is also unknown. We have recently
shown that FEN1 (2) may be regulated at the mRNA level;
whereas for pol b levels, gene copy number changes as well as
mRNA regulation may contribute to low expression (1).
PARP inhibitors that block single-strand break repair
(SSBR), a pathway related to BER, have shown clinical
benefit in BRCA1/2 germ line-deficient breast and ovarian
cancers. Moreover, emerging evidence also suggests that
triple negative breast cancers with BRCAness phenotype
may also be suitable for synthetic lethality targeting using
PARP inhibitors. The data presented in this study provide a
tantalizing possibility for a similar synthetic lethality tar-
geting in BER-deficient ER + breast cancers using inhibitors
of DSB repair pathway such as those targeting ATM, ATR,
and DNA-PKcs that are currently undergoing pharmaceutical
drug development. To provide evidence that such an ap-
proach is feasible, we have recently shown that XRCC1-
deficient cancer cells are sensitive to ATM, DNA-PKcs, and
ATR inhibitors (8).
In conclusion, BER status has prognostic and predictive
significance in ER + breast cancer patients. BER status-
directed personalized therapy may be a promising approach
in ER + breast cancer.
Notes
We investigated a consecutive series of 1406 patients with
primary ERa positive invasive breast carcinomas who were
diagnosed between 1986 and 1999 and entered into the Not-
tingham Tenovus Primary Breast Carcinoma series. All pa-
tients were treated uniformly in a single institution with a 20
year long-term clinical follow-up data and have previously
been investigated in a wide range of biomarker studies (1, 2).
The baseline demographics data have been summarized in
previous publications (1, 2). Briefly, patients received stan-
dard surgery (mastectomy or wide local excision) with ra-
diotherapy. Before 1989, patients did not receive systemic
adjuvant treatment (AT). After 1989, AT was scheduled based
on prognostic and predictive factor status, including Not-
tingham prognostic index (NPI), ERa status, and menopausal
status. Patients with NPI scores of < 3.4 (low risk) did not
receive AT. In premenopausal patients with NPI scores of
‡ 3.4 (high risk), classical cyclophosphamide, methotrexate,
and 5-flourouracil (CMF) chemotherapy was given; patients
with ERa-positive tumors were also offered HT. Post-
menopausal patients with NPI scores of ‡ 3.4 and ERa posi-
tivity were offered HT, while ERa-negative patients received
classical CMF chemotherapy. The Reporting Recommenda-
tions for Tumor Marker Prognostic Studies (REMARK) cri-
teria were followed throughout this study. This work was
approved by Nottingham Research Ethics Committee. Tissue
microarray (TMAs) were constructed and immunohisto-
chemically profiled for Pol b, FEN1, APE1, XRCC1,
SMUG1, PARP1, ATR, ATM, Chk1, Chk2, p53, BRCA1,
DNA-PKcs, and TOPO2. Table 2 summarizes antigens, pri-
mary antibodies, clone, source, optimal dilution, and scoring
system used for each immunohistochemical marker. We have
reported the specificity of the antibodies used here in previous
publications (1, 2). To validate the use of TMAs for im-
munophenotyping, full-face sections of 40 cases were stained
and protein expression levels were compared. The concor-
dance between TMAs and full-face sections was excellent
(k= 0.8). Positive and negative (by omission of the primary
antibody and IgG-matched serum) controls were included in
each run. Whole field inspection of the core was scored, and
intensities of nuclear staining were grouped as follows: 0, no
staining; 1, weak staining; 2, moderate staining; 3, strong
staining. The percentage of each category was estimated (0%–
100%). H-score (range 0–300) was calculated by multiplying
intensity of staining and percentage staining. H-score cut-offs
for individual markers are summarized in Table 3. Not all
cores within the TMA were suitable for IHC analysis, as some
cores were missing or lacked tumors. IHC data for all 14 DNA
repair markers were available in 829 tumors. HER2 expression
was assessed according to the new ASCO/CAP guidelines
using chromogenic in situ hybridization. Data analysis was
performed using SPSS (version 17; SPSS, Chicago, IL).
Where appropriate, Pearson’s v2, Fisher’s exact, v2 for trend,
Student’s t-test, and ANOVAs one-way test were performed
using SPSS software (version 17; SPSS). Multivariate anal-
ysis for survival was performed using the Cox hazard model.
The proportional hazards assumption was tested using stan-
dard log-log plots. Hazard ratios and 95% confidence intervals
(95% CIs) were estimated for each variable. All tests were two
sided with a 95% CI. p-values for each test were adjusted with
Benjamini and Hochberg multiple p-value adjustment, and an
adjusted p-value of< 0.05 was considered significant. DNA
repair prognostic index was calculated from the b-values from
the multivariate analysis of individual markers. A sum of ‘‘1’’
was assigned for low expression, and b-values were assigned
for high expression. BER expression score for individual tu-
mors was calculated as a sum of individual marker scores.
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Abbreviations Used
APE-1¼AP endonuclease 1
ATM¼ ataxia telangiectasia mutated
ATR¼ ataxia telangiectasia mutated
and Rad3 related
BCSS¼ breast cancer specific survival
BER¼ base excision repair
BRCA1¼ breast cancer susceptibility gene 1
CMF¼ cyclophosphamide, methotrexate,
and 5-flourouracil 95%
CI¼ 95% confidence interval
DNA-PKcs¼DNA-dependent protein kinase
catalytic subunit
DSBs¼ double-strand breaks
ER¼ estrogen receptor
FEN1¼ flap endonuclease 1
NPI¼Nottingham prognostic index
NST¼ non-specific type
PARP1¼ poly (ADP-ribose) polymerase 1
pol b¼DNA polymerase b
ROS¼ reactive oxygen species
SMUG1¼ single-strand monofunctional uracil
glycosylase-1
SSBR¼ single-strand break repair
SSB¼ single-strand breaks
TMA¼ tissue microarray
TOPO2¼ topoisomerase 2
XRCC1¼X-ray cross-complementation
group 1 protein
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